Moreover, data presented in this study provides proof-of-concept that SUMO pathway inhibition at the levels of E1 (SAE2) and E2 enzymes (UBC9) is sufficient to compromise cancer cell survival beyond breast cancer and lymphoma. Here, UBA2 is linked to breast cancer.